Skip to main content

How long can you take Copaxone?

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 30, 2025.

Official Answer by Drugs.com

Copaxone (glatiramer acetate) is a combination of four amino acids that may be used to treat relapsing forms of multiple sclerosis (MS) in adults, such as clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Copaxone is considered a long-term treatment for MS and it has been available for the treatment of MS for more than ten years. Copaxone has been shown to significantly reduce the number of relapses in people with MS.

Warning

Copaxone may cause severe, potentially life-threatening allergic reactions (anaphylaxis) at any time during treatment - from first dose to years later. Seek immediate emergency care if you experience:

These reactions can occur within 1 hour of injection, even without prior allergic history.

How does Copaxone work?

Experts aren’t sure exactly how Copaxone works in MS but it is thought to modify immune processes that are believed to be responsible for the development of MS.

Research has shown that after administration of glatiramer, glatiramer-specific suppressor T-cells are induced and activated in the peripheral nervous system. Although glatiramer is thought to modify the immune system response to MS, it does not appear to modify naturally occurring immune responses, although this has not been systematically evaluated.

Glatiramer acetate is a combination of the acetate salts of four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine.

Copaxone reduces the frequency of relapses, and some studies have reported a delay in the progression of the disease.

How is Copaxone given?

Copaxone is given by subcutaneous injection (under the skin) into the arms, abdomen, hips, or thighs. There are two recognized strengths of Copaxone, 20mg/ml and 40mg/ml, and the following specific dosing schedules correspond to each one:

How effective is Copaxone?

Copaxone significantly reduces the number of relapses in people with MS. The results from two separate trials have reported:

References

See also:

Related medical questions

Drug information

Related support groups